Original Research

Phototoxic and Photoallergic Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch Studies

Author and Disclosure Information

Two phase 1 patch studies were conducted to evaluate tazarotene foam 0.1% for phototoxic (study A) and photoallergic (study B) potential. In study A, 38 participants were exposed to patches containing tazarotene foam 0.1%, vehicle foam, or no foam (blank patch) over 24 hours. One set each was exposed to UV irradiation, UV and visible (VIS) light, and no irradiation. In study B, 59 participants received patches containing tazarotene foam 0.1% and vehicle foam; sites were exposed to UVB irradiation and VIS light after each application during the induction phase. After 10 to 17 days, participants received both UVA and UVA/UVB irradiation, UVA/UVB plus VIS irradiation, or no irradiation during the challenge phase. Erythema grades and local skin reactions did not differ systematically by study product or across patch sites, and no pattern of increased reactivity at tazarotene foam 0.1% sites was observed. None of the participants demonstrated conclusive photoallergic reactions. Findings suggest that tazarotene foam 0.1% is not a major photoirritant and has a low potential for phototoxic or photoallergic reactions.


 

Recommended Reading

Derm Research Unsettles Ped's Treatment of Acne
MDedge Dermatology
Acne Severity Grading Scale in the Works
MDedge Dermatology
Acne Prescriptions for Topical Combination Therapy Rising
MDedge Dermatology
Adult Acne Woes: The Skinny Podcast
MDedge Dermatology
Low-Dose Isotretinoin Tames Adult Acne
MDedge Dermatology
Whey Protein Precipitating Moderate to Severe Acne Flares in 5 Teenaged Athletes
MDedge Dermatology
Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors: Treatment With Oral Isotretinoin
MDedge Dermatology
Combined Oral Contraceptives for the Treatment of Acne: A Practical Guide
MDedge Dermatology
Acne and Whey Protein Supplementation
MDedge Dermatology
Cumulative Irritation Potential and Contact Sensitization Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch Studies
MDedge Dermatology